Literature DB >> 8862258

Primary dapsone resistance in Cebu, The Philippines; cause for concern.

E dela Cruz1, R V Cellona, M V Balagon, L G Villahermosa, T T Fajardo, R M Abalos, E V Tan, G P Walsh.   

Abstract

At a time when primary dapsone resistance was prevalent in many leprosy endemic areas, Cebu in The Philippines reported only 3.6% in the period 1975-1978 and later 8.1% in the period 1979-1982. In our current study of patients in the period 1988-1992, the number increased dramatically to 52.7%. In addition, 7.9% of the isolates are highly resistant to dapsone, a level of resistance not seen in earlier studies. This finding could have severe ramifications to the World Health Organization's multidrug therapy (WHO-MDT) mode of treatment, where dapsone is one of the principal drugs. Moreover, the increase in primary dapsone resistance may be a contributing factor in the recent finding that there has been no decline in the number of new cases found in Cebu, even after the implementation of WHO-MDT in 1985. There is a need for new drugs that could be included in the multidrug treatment for multibacillary and paucibacillary leprosy.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8862258

Source DB:  PubMed          Journal:  Int J Lepr Other Mycobact Dis        ISSN: 0148-916X


  9 in total

1.  Real-time PCR and high-resolution melt analysis for rapid detection of Mycobacterium leprae drug resistance mutations and strain types.

Authors:  Wei Li; Masanori Matsuoka; Masanori Kai; Pratibha Thapa; Saraswoti Khadge; Deanna A Hagge; Patrick J Brennan; Varalakshmi Vissa
Journal:  J Clin Microbiol       Date:  2011-12-14       Impact factor: 5.948

2.  Molecular drug susceptibility testing and genotyping of Mycobacterium leprae strains from South America.

Authors:  Pushpendra Singh; Philippe Busso; Alberto Paniz-Mondolfi; Nacarid Aranzazu; Marc Monot; Nadine Honore; Andrea de Faria Fernandes Belone; Marcos Virmond; Maria Esther Villarreal-Olaya; Carlos Rivas; Stewart T Cole
Journal:  Antimicrob Agents Chemother       Date:  2011-03-28       Impact factor: 5.191

3.  Simultaneous detection of Mycobacterium leprae and its susceptibility to dapsone using DNA heteroduplex analysis.

Authors:  D L Williams; T L Pittman; T P Gillis; M Matsuoka; Y Kashiwabara
Journal:  J Clin Microbiol       Date:  2001-06       Impact factor: 5.948

4.  Transmission of dapsone-resistant leprosy detected by molecular epidemiological approaches.

Authors:  Wei Li; Rama M Sakamuri; Danielle E Lyons; Florenda M Orcullo; Vidyagouri Shinde; Edred Lao Dela Pena; Armi A Maghanoy; Irene B Mallari; Esterlina V Tan; Indira Nath; Patrick J Brennan; Marivic Balagon; Varalakshmi Vissa
Journal:  Antimicrob Agents Chemother       Date:  2011-08-22       Impact factor: 5.191

5.  Dihydropteroate synthase of Mycobacterium leprae and dapsone resistance.

Authors:  D L Williams; L Spring; E Harris; P Roche; T P Gillis
Journal:  Antimicrob Agents Chemother       Date:  2000-06       Impact factor: 5.191

Review 6.  The continuing challenges of leprosy.

Authors:  D M Scollard; L B Adams; T P Gillis; J L Krahenbuhl; R W Truman; D L Williams
Journal:  Clin Microbiol Rev       Date:  2006-04       Impact factor: 26.132

7.  Rapid variable-number tandem-repeat genotyping for Mycobacterium leprae clinical specimens.

Authors:  Miyako Kimura; Rama Murthy Sakamuri; Nathan A Groathouse; Becky L Rivoire; David Gingrich; Susan Krueger-Koplin; Sang-Nae Cho; Patrick J Brennan; Varalakshmi Vissa
Journal:  J Clin Microbiol       Date:  2009-04-22       Impact factor: 5.948

8.  Leprosy Drug Resistance Surveillance in Colombia: The Experience of a Sentinel Country.

Authors:  Camilo Beltrán-Alzate; Fernando López Díaz; Marcela Romero-Montoya; Rama Sakamuri; Wei Li; Miyako Kimura; Patrick Brennan; Nora Cardona-Castro
Journal:  PLoS Negl Trop Dis       Date:  2016-10-05

9.  Assessment of vocation of rifabutin and rifapentine in replace of rifampcin in drug resistance leprosy patients: a molecular simulation study.

Authors:  Partha Sarathi Mohanty; Farah Naaz; Avi Kumar Bansal; Umesh Datta Gupta
Journal:  Mol Biol Res Commun       Date:  2017-09
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.